Advaxis - 48 Year Dividend History | ADXS

Historical dividend payout and yield for Advaxis (ADXS) since 1971. The current TTM dividend payout for Advaxis (ADXS) as of April 18, 2019 is $0.00. The current dividend yield for Advaxis as of April 18, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.006B
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $109.313B 12.32
Gilead Sciences (GILD) United States $80.293B 10.22
Bio-Techne Corp (TECH) United States $7.144B 48.13